Marshall Wace North America L.P. cut its stake in shares of Kezar Life Sciences Inc (NASDAQ:KZR) by 22.4% in the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 85,830 shares of the company’s stock after selling 24,748 shares during the quarter. Marshall Wace North America L.P. owned 0.45% of Kezar Life Sciences worth $1,838,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other hedge funds also recently modified their holdings of the company. Laurion Capital Management LP purchased a new stake in Kezar Life Sciences in the 2nd quarter worth approximately $173,000. BlackRock Inc. purchased a new stake in Kezar Life Sciences in the 2nd quarter worth approximately $173,000. Prosight Management LP lifted its holdings in Kezar Life Sciences by 25.5% in the 3rd quarter. Prosight Management LP now owns 52,331 shares of the company’s stock worth $1,120,000 after buying an additional 10,640 shares during the period. MYDA Advisors LLC purchased a new stake in Kezar Life Sciences in the 2nd quarter worth approximately $213,000. Finally, EcoR1 Capital LLC lifted its holdings in Kezar Life Sciences by 1.3% in the 3rd quarter. EcoR1 Capital LLC now owns 1,288,198 shares of the company’s stock worth $27,580,000 after buying an additional 16,000 shares during the period. Institutional investors own 47.40% of the company’s stock.

KZR has been the subject of several research analyst reports. Zacks Investment Research cut Kezar Life Sciences from a “hold” rating to a “sell” rating in a report on Wednesday, October 24th. ValuEngine cut Kezar Life Sciences from a “buy” rating to a “hold” rating in a report on Thursday. One investment analyst has rated the stock with a hold rating and five have assigned a buy rating to the company’s stock. Kezar Life Sciences currently has a consensus rating of “Buy” and an average target price of $27.33.

KZR stock opened at $29.98 on Friday. Kezar Life Sciences Inc has a twelve month low of $14.77 and a twelve month high of $36.33.

Kezar Life Sciences (NASDAQ:KZR) last posted its earnings results on Thursday, November 8th. The company reported ($0.30) EPS for the quarter, topping the Zacks’ consensus estimate of ($0.48) by $0.18. On average, equities analysts anticipate that Kezar Life Sciences Inc will post -2.22 earnings per share for the current fiscal year.

COPYRIGHT VIOLATION NOTICE: “Marshall Wace North America L.P. Has $1.84 Million Position in Kezar Life Sciences Inc (KZR)” was reported by Watch List News and is owned by of Watch List News. If you are reading this piece on another publication, it was illegally copied and republished in violation of US & international trademark and copyright laws. The original version of this piece can be read at https://www.watchlistnews.com/marshall-wace-north-america-l-p-has-1-84-million-position-in-kezar-life-sciences-inc-kzr/2688408.html.

Kezar Life Sciences Profile

Kezar Life Sciences, Inc, a clinical-stage biotechnology company, engages in the discovery and development of small molecule therapeutics to treat unmet needs in autoimmunity and cancer in the United States. Its lead product candidate, KZR-616, a selective immunoproteasome inhibitor that is in Phase 1b/2 clinical trials in lupus and lupus nephritis The company was incorporated in 2015 and is headquartered in South San Francisco, California.

Featured Article: Inflation

Want to see what other hedge funds are holding KZR? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Kezar Life Sciences Inc (NASDAQ:KZR).

Institutional Ownership by Quarter for Kezar Life Sciences (NASDAQ:KZR)

Receive News & Ratings for Kezar Life Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kezar Life Sciences and related companies with MarketBeat.com's FREE daily email newsletter.